James has a Master’s in Biochemistry from the University of Sheffield, UK and joined Hanson Wade in 2009 soon after graduating. He’s worked at all levels of the conference business conducting scientific research and understanding oncology market dynamics; but has an especial interest in antibody-drug conjugates. As the original architect of Beacon 1.0, he launched the first modules (ADC and Checkpoint Monotherapies) and developed the product and team through its start-up years (2015-2017). Since 2021, he’s been focused on building Hanson Wade Intelligence, the market research and consulting division of the business.